Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits

Brain Research

Volumn 850, Issue 1-2, 1999, Pages 104-117

  Garcia Jimenez A ^a   Cowburn, R F ^a   Ohm, T G ^b   Bogdanovic, N ^a   Winblad, B ^a   Fastbom, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

3H Forskolin; Adenylyl cyclase; Alzheimer's disease; Autoradiography; Entorhinal cortex; G protein; Guanylyl 5' imidodiphosphate; Hippocampus; Signal transduction

Indexed keywords

ADENYLATE CYCLASE; AMYLOID; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLYLIMIDODIPHOSPHATE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ENTORHINAL CORTEX; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; AGING; BINDING SITE; BRAIN; BRAIN LEVEL; CADAVER; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SENILE PLAQUE;

ADENYLATE CYCLASE; AGED; AGING; ALZHEIMER DISEASE; AUTORADIOGRAPHY; BINDING SITES; BRAIN; BRAIN CHEMISTRY; FORSKOLIN; GTP-BINDING PROTEINS; GUANYLYL IMIDODIPHOSPHATE; HUMANS; NEUROFIBRILLARY TANGLES; POSTMORTEM CHANGES; SENILE PLAQUES;

EID: 0032585746     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02111-3     Document Type: Article

References (45)

1. American Psychiatric Association, Committee on Nomenclature and Statistics, Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., revised. American Psychiatric Association, Washington, DC, 1987.
2. 2+/Calmodulin and neurotransmitter stimulation of adenylate cyclase in striatum and hippocampus. Cell Mol. Neurobiol. 8:1988;459-469.
3. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
4. 7A receptor. J. Biol. Chem. 273:1998;17469-17476.
5. Barrionuevo G., Brown T.H. Associative long-term potentiation in hippocampal slices. Proc. Natl. Acad. Sci. USA. 80:1983;7347-7351.
6. erk beyond phosphorylation by cAMP-dependent PKA: relation to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200:1994;187-194.
7. Blennow K., Cowburn R.F. The neurochemistry of Alzheimer's disease. Acta Neurol. Scand. Suppl. 168:1996;77-86.
8. 3H ]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits Brain Res. 818:1999;383-396.
9. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. Berlin. 82:1991;239-259.
10. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65:1995;1431-1444.
11. 2+-sensitive adenylyl cyclases. Cell Signal. 6:1994;823-840.
12. Cowburn R.F., Fowler C.J., O'Neill C. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurol. Scand. Suppl. 165:1996;25-32.
13. Cowburn R.F., O'Neill C., Ravid R., Alafuzoff I., Winblad B., Fowler C.J. Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimer's disease. J. Neurochem. 58:1992;1409-1419.
14. i-protein inhibited adenylyl cyclase activity in the brains of patients with Alzheimer's disease. Neurosci. Lett. 141:1992;16-20.
15. 3H ]forskolin binding sites in Alzheimer's disease: a quantitative autoradiographic study Brain Res. 511:1990;241-248.
16. Efthimiopoulos S., Punj S., Manolopoulos V., Pangalos M., Wang G.P., Refolo L.M., Robakis N.K. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein. J. Neurochem. 67:1996;872-875.
17. Fastbom J., Ohm T.G., Bonkale W.L., Kurumatani T., Winblad B., Cowburn R.F. Signal transduction mechanisms in Alzheimer's disease. Int. Acad. Biomed. Drug Res. 13:1998;110-116.
18. i NeuroReport. 9:1998;3329-3333.
19. Geary W.A., Toga A.W., Wooten G.F. Quantitative film autoradiography for tritium: methodological considerations. Brain Res. 337:1985;99-108.
20. Gegelashvili G., Bock E., Schousboe A., Linnemann D. Two types of amyloid precursor protein (APP) mRNA in rat glioma cell lines: upregulation via a cyclic AMP-dependent pathway. Mol. Brain Res. 37:1996;151-156.
21. 3H ]forskolin binding in the rat brain by guanylyl-5′-imidodiphosphate and sodium fluoride: comparison with the distribution of guanine nucleotide binding sites J. Pharmacol. Exp. Ther. 239:1986;952-958.
22. 3H ]forskolin binding sites in the rat brain Brain Res. 361:1985;351-360.
23. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewsky H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 83:1986;4913-4917.
24. Hyman B.T., van Hoesen G.W., Damasio A.R. Memory-related neural systems in Alzheimer's disease: an anatomic study. Neurology. 40:1990;1721-1730.
25. 2+/calmodulin-dependent protein kinase II: metabolic and functional consequences. J. Neurochem. 59:1992;2056-2062.
26. Kurumatani T., Fastbom J., Bonkale W.L., Bogdanovic N., Winblad B., Ohm T.G., Cowburn R.F. Loss of inositol 1,4,5-triphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res. 796:1998;209-221.
27. Marambaud P., Wilk S., Checler F. Protein kinase A phosphorylation of the proteasome: a contribution to the α-secretase pathway in human cells. J. Neurochem. 67:1996;2616-2619.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 34:1984;939-944.
29. 2+-insensitive adenylyl cylases in the rat brain. Synapse. 14:1993;51-59.
30. O'Neill C., Wiehager B., Fowler C.J., Ravid R., Winblad B., Cowburn R.F. Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain. Brain Res. 636:1994;193-201.
31. Ohm T.G., Bohl J., Lemmer B. Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes. Brain Res. 540:1991;229-236.
32. Ohm T.G., Müller H., Braak H., Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience. 64:1995;209-217.
33. Ohm T.G., Schmitt M., Bohl J., Lemmer B. Decrease is adenylate cyclase activity antecedes neurofibrillary tangle formation. Neurobiol. Aging. 18:1997;275-279.
34. Paterson J.M., Smith S.M., Harmar A.J., Antoni F.A. Control of a novel adenylyl cyclase by calcineurin. Biochem. Biophys. Res. Commun. 214:1995;1000-1008.
35. Poat J.A., Cripps H.E., Iversen L.L. Differences between high-affinity forskolin binding sites in dopamine-rich and other regions of rat brain. Proc. Natl. Acad. Sci. USA. 85:1988;3216-3220.
36. Ross B.M., McLaughlin M., Roberts M., Milligan G., McCulloch J., Knowler J.T. Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease. Brain Res. 622:1993;35-42.
37. Schnecko A., Witte K., Bohl J., Ohm T., Lemmer B. Adenylyl cyclase activity in Alzheimer's disease brain, stimulatory and inhibitory signal transduction pathways are differently affected. Brain Res. 644:1994;291-296.
38. Scott C.W., Spreen R.C., Herman J.L., Chow F.P., Davison M.D., Young J., Caputo C.B. Phosphorylation of recombinant Tau by cAMP-dependent protein kinase. J. Biol. Chem. 268:1993;1166-1173.
39. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., Singh T.J. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell Biochem. 167:1997;99-105.
40. Singh T.J., Zaidi T., Grundke-Iqbal I., Iqbal K. Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer's disease brain. Mol. Cell Biochem. 154:1996;143-151.
41. 3H ]forskolin binding sites in the human caudate nucleus Brain Res. 610:1993;156-161.
42. Van Hoesen G.W., Hyman B.T., Damasio A.R. Entorhinal cortex pathology in Alzheimer's disease. Hippocampus. 1:1991;1-8.
43. Xia Z., Storm D.R. Calmodulin-regulated adenylyl cyclases and neuromodulation. Curr. Opin. Neurobiol. 7:1997;391-396.
44. Yamamoto M., Ozawa H., Saito T., Frölich L., Riederer P., Takahata N. Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type. NeuroReport. 7:1996;2965-2970.
45. 2+/CaM-sensitive adenylyl cyclase activity is decreased in the Alzheimer's brain: possible relation to type I adenylyl cyclase. J. Neural. Transm. 104:1997;721-732.